Clinical trials: Lymphoma, Non-Hodgkins
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable…
- Trial name
- NCT00504205
- Testing
- multitargeted receptor tyrosine kinase inhibitor MP470, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
This phase I trial is studying the best dose of 3-AP and the side effects of giving 3-AP together with gemcitabine in treating patients with advanced solid tumors or lymphoma.
- Conditions
- Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma
- Trial name
- NCT00293345
- Testing
- gemcitabine hydrochloride, triapine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Non-Hodgkins Lymphoma
Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma
Researchers hope to learn if adding rituximab with high doses of chemotherapy and stem cell transplantation will help patients get rid of their lymphoma cells from the bone marrow and stem cell collections.
- Trial name
- NCT00856245
- Testing
- Rituximab
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Kansas Medical Center
Non-Hodgkins Lymphoma, Hodgkins Lymphoma
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
The administration of allogeneic third party derived LMP specific-CTLs (special peripheral blood cells from another person) that are made specific to fight EBV infection) in Children, Adolescents and Young Adults (CAYA) with…
- Conditions
- Non-Hodgkins Lymphoma, Hodgkins Lymphoma, Lymphoproliferative Disorder
- Trial name
- NCT02057445
- Testing
- EBV CTL's, Peripheral Blood Donor
- Where
- 2 sites in United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- New York Medical College
Lymphoma
VP and G-CSF With or Without Rituximab in Autologous Peripheral Stem Cell Transplant For NHL
RATIONALE: Drugs used in chemotherapy, such as busulfan, etoposide, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00274794
- Testing
- filgrastim, rituximab
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- The Cleveland Clinic
Lymphoma, B-Cell, Small Lymphocytic Lymphoma
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
This study aims to evaluate the safety, tolerability, pharmacodynamic, and pharmacokinetic (PK) of nemtabrutinib (formerly ARQ 531) tablets in selected participants with relapsed or refractory hematologic malignancies.
- Conditions
- Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
- Trial name
- NCT03162536
- Testing
- Nemtabrutinib
- Where
- 10 sites in United States
- Volunteers
- 190 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma
This phase I trial studies the side effects and best dose of fludarabine (fludarabine phosphate) when given together with iodine I 131 tositumomab in treating older patients who are undergoing an autologous or syngeneic stem cell…
- Conditions
- Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00110071
- Testing
- fludarabine phosphate, peripheral blood stem cell transplantation, iodine I 131 tositumomab
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
This clinical trial studies fludarabine phosphate, low-dose total-body irradiation, and donor stem cell transplant followed by cyclosporine, mycophenolate mofetil, and donor lymphocyte infusion in treating patients with…
- Conditions
- Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma
- Trial name
- NCT00006251
- Testing
- total-body irradiation, fludarabine phosphate, cyclosporine
- Where
- 2 sites in United States, Italy
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Graft Versus Host Disease, Leukemia
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
RATIONALE: Giving chemotherapy before a donor bone marrow transplant or peripheral stem cell transplant helps stop the growth of cancer cells and helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00611351
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Nebraska
Brain and Central Nervous System Tumors, Lymphoma
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Gene therapy may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003567
- Testing
- filgrastim, sargramostim, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00290667
- Testing
- pegfilgrastim, rituximab, cyclophosphamide
- Where
- 338 sites in Czechia, France and 7 more
- Volunteers
- 586 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Cancer
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
RATIONALE: Antifungals, such as voriconazole and itraconazole, may be effective in preventing fungal infections in patients who are undergoing allogeneic stem cell transplantation.
- Trial name
- NCT00079222
- Testing
- itraconazole, voriconazole
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Cancer
Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation
RATIONALE: Captopril may protect the lungs from the side effects of bone marrow or stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of captopril to lessen the side effects in patients…
- Trial name
- NCT00004230
- Testing
- captopril, cyclophosphamide, autologous bone marrow transplantation
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Northwestern University
Lymphoma, Small Intestine Cancer
BMS-247550 in Treating Patients With Advanced Cancers
Phase I trial to study the effectiveness of BMS-247550 in treating patients who have malignant solid tumors or lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00006221
- Testing
- ixabepilone
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
RATIONALE: Chemotherapy, such as busulfan, melphalan, and thiotepa, may destroy cancerous blood-forming cells (stem cells) in the blood and bone marrow.
- Trial name
- NCT00238433
- Testing
- filgrastim, busulfan, melphalan
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- OHSU Knight Cancer Institute
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Carbendazim in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of carbendazim in treating patients who have advanced…
- Trial name
- NCT00023816
- Testing
- carbendazim
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer, Chronic Myeloproliferative Disorders
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
RATIONALE: Alemtuzumab and glucocorticoids, such as prednisone or methylprednisolone, may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell transplant.
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease
- Trial name
- NCT00410657
- Testing
- alemtuzumab, methylprednisolone, prednisone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
RATIONALE: Beclomethasone dipropionate may be effective in preventing acute graft-versus-host disease in patients undergoing a stem cell transplant for hematologic cancer.
- Conditions
- Hematopoietic/Lymphoid Cancer, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00489203
- Testing
- beclomethasone dipropionate, tacrolimus, methotrexate
- Where
- 2 sites in United States
- Volunteers
- 140 people
- Sponsor
- Fred Hutchinson Cancer Center
B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer
Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma
- Trial name
- NCT00010192
- Testing
- rituximab, aldesleukin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Adult Grade III Lymphomatoid Granulomatosis, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
This phase I trial is studying the side effects and best dose of SB-715992 in treating patients with metastatic or unresectable solid tumors or Hodgkin's or non-Hodgkin's lymphoma.
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma
- Trial name
- NCT00101244
- Testing
- ispinesib, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)